Astellas joins Pfizer in emerging North Carolina hub, unveiling new $100M gene therapy manufacturing site
The small city of Sanford, NC, was once known for its brick production, but now is quickly becoming a hub in the biotech world. And now Astellas is the latest to pitch its tent in the area.
The company’s gene therapy branch, which came out of the acquisition of Audentes in 2019, has opened a new manufacturing facility in the city, comprising 135,000 square feet and shelling out $100 million. Astellas designed the site to provide clinical and commercial-scale manufacturing capabilities for its pipeline of AAV vectors for gene therapies, which includes programs from both Astellas and Audentes’ portfolios.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.